Modelling the global spread of diseases: A review of current practice and capability

• Published in: Epidemics 2018-12, Vol.25, p.1-8
• Main Authors: Walters, Caroline E., Meslé, Margaux M.I., Hall, Ian M.
• Format: Article
• Language: English
• Subjects: Communicable Diseases - epidemiology; Communicable Diseases - transmission; Disease Outbreaks - statistics & numerical data; Disease spread; Humans; Influenza; Mathematical modelling; Models, Theoretical; Reproducibility of Results; Scoping review; Travel
• ISSN: 1755-4365; 1878-0067
• DOI: 10.1016/j.epidem.2018.05.007

•Scoping review: mathematical models for global disease spread.•Extracted information: modelling method, input and validation data sources.•Model validation uncommon, perhaps a result of limited data availability.•Commercial data use has implications for review and reproducibility of results. Mathematical models can aid in the understanding of the risks associated with the global spread of infectious diseases. To assess the current state of mathematical models for the global spread of infectious diseases, we reviewed the literature highlighting common approaches and good practice, and identifying research gaps. We followed a scoping study method and extracted information from 78 records on: modelling approaches; input data (epidemiological, population, and travel) for model parameterization; model validation data. We found that most epidemiological data come from published journal articles, population data come from a wide range of sources, and travel data mainly come from statistics or surveys, or commercial datasets. The use of commercial datasets may benefit the modeller, however makes critical appraisal of their model by other researchers more difficult. We found a minority of records (26) validated their model. We posit that this may be a result of pandemics, or far-reaching epidemics, being relatively rare events compared with other modelled physical phenomena (e.g. climate change). The sparsity of such events, and changes in outbreak recording, may make identifying suitable validation data difficult. We appreciate the challenge of modelling emerging infections given the lack of data for both model parameterisation and validation, and inherent complexity of the approaches used. However, we believe that open access datasets should be used wherever possible to aid model reproducibility and transparency. Further, modellers should validate their models where possible, or explicitly state why validation was not possible.